Swiss study tracks how IBD patients use Gut-Targeting medication
NCT ID NCT04989907
Summary
This study observed how 92 Swiss adults with Crohn's disease or ulcerative colitis used vedolizumab medication in real-world clinic settings. Researchers tracked whether patients received the drug through IV infusions or under-the-skin injections, and monitored how long they stayed on treatment over two years. The goal was to understand real-world treatment patterns, not to test new treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHNS DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Bauchzentrum INSELSPITAL, Universitatsspital Bern
Bern, 3010, Switzerland
-
Clarunis AG
Basel, 4002, Switzerland
-
Gastroenterologische Praxis Balsiger, Seibold & Partner Crohn-Colitis-Zentrum
Bern, 3012, Switzerland
-
Kantonsspital St. Gallen
Sankt Gallen, Canton of St. Gallen, 9007, Switzerland
-
Universitatsspital Zurich
Zurich, 8091, Switzerland
-
Zentrum fur Gastroenterologie und Hepatologie AG
Zurich, 8048, Switzerland
Conditions
Explore the condition pages connected to this study.